IBEX 35
9.020,40 +76,10 (+0,85%) Euro Stoxx 50
4.209,32 +41,11 (+0,99%) Dólar/Euro
1,0857 +0,0009 (+0,09%) Petróleo Brent
79,43 +0,78 (+0,99%) Oro
1.969,20 -4,30 (-0,22%) Bitcoin EUR
26.176,64 +1.550,12 (+6,29%)
Pfizer Inc. (PFE)
Antes de la apertura:
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001-2192
United States
212 733 2323
https://www.pfizer.com
Sector(es): Healthcare
Sector: Drug Manufacturers—General
Empleados a tiempo completo: 83.000
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Albert Bourla D.V.M., DVM, Ph.D. | Chairman & CEO | 11,72M | N/A | 1962 |
| Mr. Frank A. D'Amelio | CFO & Exec. VP | N/A | N/A | 1958 |
| Mr. David M. Denton | Chief Financial Officer & Exec. VP | 18,19M | N/A | 1965 |
| Dr. Mikael Dolsten M.D., Ph.D. | Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical | 5,82M | N/A | 1958 |
| Ms. Angela Hwang | Chief Commercial Officer & Pres of Global Biopharmaceuticals Bus. | 4,89M | 7,7M | 1966 |
| Dr. William Pao M.D., Ph.D. | Exec. VP & Chief Devel. Officer | 11,26M | N/A | 1967 |
| Ms. Jennifer B. Damico | Sr. VP, Controller & Principal Accounting Officer | N/A | N/A | 1968 |
| Ms. Lidia L. Fonseca | Exec. VP and Chief Digital & Technology Officer | N/A | N/A | 1969 |
| Mr. Christopher J. Stevo CFA | Sr. VP & Chief Investor Relations Officer | N/A | N/A | N/A |
| Mr. Douglas M. Lankler | Exec. VP & Gen. Counsel | N/A | N/A | 1966 |
Descripción
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Gobierno corporativo
El ISS Governance QualityScore de Pfizer Inc., a día 1 de marzo de 2023, es 4. Las puntuaciones base son Auditoría: 10; Tablero: 5; Derechos de los accionistas: 1; Compensación: 2.
